Keywords: eu, pharma, must, act, inferior, clinical, trials
EU pharma "must act on inferior clinical trials performance," G10 meeting hears
Article | 28 January 2002
Moves to improve the competitiveness of the European pharmaceuticalindustry are starting 15 years behind, according to Peter Farrow, vice president for ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
